Genelux (GNLX) Long-Term Debt Issuances (2023)

Genelux's (GNLX) quarterly Long-Term Debt Issuances came in at $215000.0 in Q4 2023, up 200.0% quarter-over-quarter from -$215000.0 in Q3 2023.

Genelux (GNLX) Long-Term Debt Issuances (2023) Analysis & Trends

Genelux's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $215000.0 for Q4 2023.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $215000.0 in Q4 2023; TTM through Dec 2023 was $900000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $900000.0, down 18.18% from the prior year.
Long-Term Debt Issuances grew to $215000.0 in Q4 2023 per GNLX's latest filing, from -$215000.0 in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $900000.0 in Q1 2023 and bottomed at -$215000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	65,899.61 Bn	65,899.33 Bn	-	-
2	Nanobiotix	1,933.82 Bn	1,933.76 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-
4	BeOne Medicines	471.67 Bn	466.88 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	122.32 Bn	115.07 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	70.04 Bn	61.29 Bn	3.31 Bn	-
7	Belite Bio	62.06 Bn	62.06 Bn	-	-
8	Argenx Se	55.93 Bn	50.74 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.55 Bn	34.54 Bn	959.66 Mn	-
10	Genelux	129.36 Mn	129.36 Mn	-	-

Download Data